ArticleClinical transplantation2025
Long-Term Outcomes Among Lung Transplant Recipients With High-Risk Cytomegalovirus Mismatch Managed With a Multimodality Regimen.
Article in Clinical transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms of the Indirect Effects of CMV Infection in Solid Organ Transplant Recipients: A Narrative Review.Journal of clinical medicine · 2026Review
- Second report of registry of the International Society of Uterus Transplantation (ISUTx): international activities 2000-2024.Human reproduction (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung transplant (LT) recipients with high-risk cytomegalovirus (CMV) mismatch donors (donor seropositive, recipient seronegative) have worse early and late outcomes. We sought to describe the outcomes among high-risk mismatch patients managed using proactive monitoring and multimodality prophylaxis and management protocol.
methodsWe included patients with single or bilateral lung transplants between January 2012 and December 2016 (n = 324). The patients were classified into two groups: high-risk CMV mismatch (R-/D+): n = 83 (25.6%) and non-high-risk CMV mismatch (n = 241). Post-LT follow-up period ranged from 8 to 12 years. Post-transplant survival was analyzed as the primary outcome variable.
resultsThere was no difference in LT recipients' baseline and post-transplant characteristics with and without CMV-mismatch donors. The mismatch group experienced a significantly higher frequency and burden of CMV viremia (p < 0.001) and resistant viremia (p < 0.001). Regardless, the two groups had similar long-term outcomes with no statistically significant difference in CLAD-free survival at 3 years or overall post-transplant survival. On Cox proportional hazard analysis, transplant indication was the only independent predictor of post-transplant survival (p = 0.004).
conclusionsA proactive multimodality CMV management protocol consisting of antiviral agents (ganciclovir/valganciclovir) and immune augmentation with CMV immune globulin may improve outcomes among high-risk CMV mismatch LT recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.